Potential therapy removes APOE and plaques from brain
Years before people start showing characteristic symptoms of Alzheimer’s disease, sticky plaques begin forming in their brains, damaging nearby cells. For decades, doctors have sought ways to clear out these plaques as a way to prevent or treat the disease.
The sticky clumps, known as amyloid plaques, are composed primarily of a brain protein called amyloid beta. But nestled within the plaques are small amounts of another Alzheimer’s protein: APOE. Now, researchers at Washington University School of Medicine have shown that an antibody not only targets APOE for removal but sweeps away plaques.
The findings, available March 26 in the Journal of Clinical Investigation, could lead to a way to halt the brain damage triggered by amyloid plaques while the disease is still in its early stages, perhaps before symptoms appear.
“Many people build up amyloid over many years, and the brain just can’t get rid of it,” said senior author David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology. “By removing plaques, if we start early enough, we may be able to stop the changes to the brain that result in forgetfulness, confusion and cognitive decline.”
Variants of the gene APOE are the single largest risk factor for Alzheimer’s disease. In earlier work, Holtzman and colleagues have shown that a DNA-based compound that targets APOE can lessen the injury caused by amyloid plaques.
But getting rid of the plaques likely would protect the brain better than blunting the plaques’ destructiveness. To find out whether the plaques could be removed, Holtzman, co-first authors Fan Liao, PhD, a postdoctoral researcher, and Aimin Li, PhD, a senior scientist, and colleagues focused on antibodies that recognize and bind to APOE. Once antibodies attach themselves to their APOE target, they attract the attention of roving immune cells, which carry both antibody and target off to be destroyed. The researchers reasoned that nearby amyloid might be cleared away along with APOE.
The researchers tested several antibodies that recognize human APOE in mice genetically predisposed to develop amyloid plaques. The APOE genes of the mice had been replaced with a human APOE gene. The antibodies were developed in collaboration with Denali Therapeutics.
For six weeks, the mice were given weekly injections of placebo or antibodies against APOE. Then, the researchers measured the amount of plaques in their brains. One antibody – called HAE-4 – cut the level of plaques by half.
Moreover, HAE-4 had no effect on APOE levels in the blood. APOE plays an important role in transporting fats and cholesterol in the body, so removing it from the bloodstream could create unwanted side effects. The failure of the antibody to lower levels of APOE in the blood was therefore a good sign. But it was also a mystery. Why did the antibody clear APOE from the brain but not the blood?
“It turns out that the APOE in the plaques has a different structure than the form of APOE found in the blood,” Holtzman said. “The HAE-4 antibody recognized only the form found attached to the plaques in the brain.”
No treatment exists to prevent or delay onset – or slow the trajectory – of Alzheimer’s disease. But a few antibodies that clear plaques by targeting amyloid beta are being evaluated in clinical trials. While such antibodies are promising, they sometimes come with the side effect of inflammation and swelling in the brain.
However, antibodies that target APOE may be successful at removing plaques in people and somewhat less likely to trigger a destructive immune response, Holtzman said.
“The anti-amyloid antibodies are going to be binding to most of the molecules that are in the plaque, but the anti-APOE antibody would target just a very small component of the plaque,” Holtzman said. “This means we may find less immune activation, and we might not see the unwelcome side effects.”
The researchers are planning further studies to determine whether similar antibodies are safe and might be effective enough to be used in people.
The Latest on: Alzheimer’s plaques
via Google News
The Latest on: Alzheimer’s plaques
- Mass spectrometry to detect key markers of Alzheimer'son May 19, 2022 at 8:18 am
A group of Skoltech scientists led by Professor Evgeny Nikolaev in collaboration with colleagues from MIPT, Engelhardt Institute of Molecular Biology of RAS, and Emanuel Institute of Biochemical ...
- Alzheimer's Disease: The Inevitable Presence of Absenceon May 18, 2022 at 3:36 pm
"To a person who loves, is not absence the most certain...the most durable, the most indestructible...of presences"? (Proust, Pleasure and Days, 1896.) Nowhere does Proust's quotation resonate more ...
- What to Know About the Alzheimer’s Vaccines Currently in Developmenton May 18, 2022 at 9:00 am
Below are the Alzheimer’s disease vaccines currently undergoing clinical trials. Many, but not all, people with Alzheimer’s disease will have a buildup of beta-amyloid plaques. It’s not clear exactly ...
- Florida clinical trial shows promise in fighting Alzheimer's diseaseon May 17, 2022 at 7:27 pm
50 AND THEY SLOWLY OVER TIME, OVER A DECADE OR TWO, BIND TO THE BRAIN AND CREATE PLAQUES. THE DEVELOPMENT OF T DIAGNOSTIC BLOOD TEST AND THE FOCUS ON PREVENTION IS REALLY CHANGING THE APPROACH AND ...
- Nevada, home to top neurology center, has third-fastest rate of growth for Alzheimer’s diseaseon May 17, 2022 at 11:04 am
Nevada has the third-fastest rate of growth for Alzheimer’s disease. Between now and 2025, the number of Nevadans with dementia is expected to grow almost 31% from 49,000 to 64,000. By 2050, Nevada ...
- Alzheimer’s Association says accelerated drug approvals necessary in search for treatmenton May 17, 2022 at 6:55 am
The drug is Aduhelm, and despite widespread enthusiasm for it among Alzheimer's patients and advocates, it hasn't been proven to slow the disease. The drug was given accelerated approval by the Food ...
- How Alzheimer's Disease and Other Dementias Differ, and How They're Misunderstoodon May 17, 2022 at 5:02 am
The physical changes that happen in a patient's brain are considered to be some of the main features of Alzheimer's disease. Amyloid plaques (or "clumps") and neurofibrillary (or "tau tangles") ...
- Trial Underway for Alzheimer's Vaccineon May 16, 2022 at 9:49 am
Almost twenty years ago, researchers at the Ann Romney Center at Brigham and Women’s Hospital began researching the possibility of a nasal vaccine to | Clinical And Molecular Dx ...
- Coverage of Alzheimer’s drug Aduhelm limited due to concerns about effectiveness, safetyon May 16, 2022 at 6:43 am
Aduhelm, an expensive Alzheimer's drug, is fomenting controversy — and generating excitement for patients. The FDA approved it last summer. But Adulem’s results are the subject of intense debate — and ...
via Bing News